| CNBX Pharmaceuticals Inc. (CNBXD) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Q1-CY2026 | Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | Q1-CY2014 | |
| Balance Sheet Date | 2025-Nov-30 | 2025-Aug-31 | 2025-May-31 | 2025-Feb-28 | 2024-Nov-30 | 2024-Aug-31 | 2024-May-31 | 2024-Feb-29 | 2021-Aug-31 | 2021-May-31 | 2021-Feb-28 | 2020-Nov-30 | 2020-Aug-31 | 2020-May-31 | 2020-Feb-29 | 2019-Nov-30 | 2019-Aug-31 | 2019-May-31 | 2019-Feb-28 | 2018-Nov-30 | 2018-Aug-31 | 2018-May-31 | 2018-Feb-28 | 2017-Nov-30 | 2017-Aug-31 | 2017-May-31 | 2017-Feb-28 | 2016-Nov-30 | 2016-Aug-31 | 2016-May-31 | 2016-Feb-29 | 2015-Nov-30 | 2015-Aug-31 | 2015-May-31 | 2015-Feb-28 | 2014-Nov-30 | 2014-Aug-31 | 2014-May-31 | 2014-Feb-28 | ||||||||||
| Fiscal Period | Q1-FY2026 | Q4-FY2025 | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q3-FY2024 | Q2-FY2024 | Q4-FY2021 | Q3-FY2021 | Q2-FY2021 | Q1-FY2021 | Q4-FY2020 | Q3-FY2020 | Q2-FY2020 | Q1-FY2020 | Q4-FY2019 | Q3-FY2019 | Q2-FY2019 | Q1-FY2019 | Q4-FY2018 | Q3-FY2018 | Q2-FY2018 | Q1-FY2018 | Q4-FY2017 | Q3-FY2017 | Q2-FY2017 | Q1-FY2017 | Q4-FY2016 | Q3-FY2016 | Q2-FY2016 | Q1-FY2016 | Q4-FY2015 | Q3-FY2015 | Q2-FY2015 | Q1-FY2015 | Q4-FY2014 | Q3-FY2014 | Q2-FY2014 | ||||||||||
| Price to Sales | |||||||||||||||||||||||||||||||||||||||||||||||||
| Price to Book | |||||||||||||||||||||||||||||||||||||||||||||||||
| Price to Earnings | |||||||||||||||||||||||||||||||||||||||||||||||||
| Price to Unlevered FCF | |||||||||||||||||||||||||||||||||||||||||||||||||
| Debt to Asset Ratio | 231.51x | 136.40x | 137.31x | 51.74x | 113.71x | 80.02x | 31.67x | 15.39x | 5.04x | .41x | .39x | .24x | .26x | .20x | .55x | .13x | .06x | .03x | .02x | .02x | .04x | .17x | .17x | .13x | .21x | 1.81x | .17x | 1.30x | 1.81x | 20.71x | 5.31x | 5.73x | 15.09x | 11.79x | 6.78x | 1.94x | .89x | .65x | 47.40x | ||||||||||
| Current Ratio | - | .01x | .01x | .02x | .01x | .01x | .03x | .06x | .09x | 1.25x | 1.45x | 1.27x | .80x | 2.04x | 3.69x | 5.49x | 6.90x | 9.81x | 11.46x | 15.80x | 17.54x | 3.01x | 4.45x | 6.27x | 4.60x | 5.03x | 5.75x | .77x | .55x | .04x | .18x | .17x | .06x | .08x | .13x | .47x | 1.07x | 1.52x | |||||||||||